Trial Outcomes & Findings for Trends in Modern Phase 1 Oncology Trials (NCT NCT03676270)

Results Overview

Number of reported responses (complete \[CR\] and partial \[PR\]) divided by the number of reported assessable patients

Recruitment status

COMPLETED

Target enrollment

6915 participants

Primary outcome timeframe

up to 6 months after treatment initiation

Results posted on

2021-01-07

224 trials were analyzed which included 6915 participants

Unit of analysis: trials

Participant milestones
Measure	Participants Included in Phase 1 Oncology Trials Participants included in Phase 1 Oncology Trials, published from January 1, 2014, through June 30, 2015.
Overall Study STARTED	6915 224
Overall Study COMPLETED	6915 224
Overall Study NOT COMPLETED	0 0

Withdrawal data not reported

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort
Measure	Trials n=6915 Participants Cancer Phase 1 trials
Age, Customized trials with participant > 18 years old	6915 Participants n=6915 Participants
Sex: Female, Male Female	3458 Participants n=6915 Participants
Sex: Female, Male Male	3457 Participants n=6915 Participants

Timeframe: up to 6 months after treatment initiation

Number of reported responses (complete \[CR\] and partial \[PR\]) divided by the number of reported assessable patients

Outcome measures
Measure	Phase 1 Oncology Trials n=6915 Participants Phase 1 Oncology Trials, published from January 1, 2014, through June 30, 2015.
Response Rate	1371 Participants

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Institut Bergonié

Phone: 335 56333333